Randomized, open-label study of the short-term pharmacokinetics of oral magnesium oxide in healthy volunteers.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Magnesium oxide, though poorly soluble with low bioavailability, is widely used for magnesium supplementation due to its high elemental content and affordability.

Parameters dependent on terminal elimination (t1/2, AUC0-∞, CL/F, MRT) were not estimated because a clear terminal log-linear phase was not identifiable within the 12-hour sampling window.

Who Took Part

The abstract describes 24 volunteers taking part.

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, men only.

How the Study Was Run

The design is described as randomized and open-label.

The volunteers were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Safety was assessed by monitoring vital signs, laboratory parameters, ECG, and adverse events.

What Was Measured

The subject headings attached to it are Magnesium Oxide, Healthy Volunteers, Area Under Curve, Biological Availability and Magnesium.

Author keywords: Drug tolerance, Oral administration and Safety.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 24 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2026 (Scientific reports), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.